Boston Trust Walden Corp Takes $22.10 Million Position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Boston Trust Walden Corp bought a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the first quarter, according to its most recent filing with the SEC. The firm bought 178,012 shares of the specialty pharmaceutical company's stock, valued at approximately $22,100,000. Boston Trust Walden Corp owned approximately 0.29% of Jazz Pharmaceuticals as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. IFP Advisors Inc acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth $25,000. Quadrant Capital Group LLC increased its position in shares of Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after acquiring an additional 101 shares during the period. Elequin Capital LP raised its stake in Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after acquiring an additional 183 shares during the last quarter. CoreFirst Bank & Trust acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth about $28,000. Finally, Allianz SE acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth about $29,000. Hedge funds and other institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ traded down $0.73 during trading hours on Friday, reaching $107.51. The company's stock had a trading volume of 1,053,788 shares, compared to its average volume of 830,550. The firm has a market capitalization of $6.51 billion, a price-to-earnings ratio of 14.33, a P/E/G ratio of 4.67 and a beta of 0.33. The company's 50-day moving average is $108.14 and its two-hundred day moving average is $120.08. The company has a debt-to-equity ratio of 1.28, a current ratio of 3.38 and a quick ratio of 2.97. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The business had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. During the same period in the previous year, the company earned $2.68 earnings per share. The company's quarterly revenue was down .5% compared to the same quarter last year. On average, equities analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $116.35, for a total transaction of $116,350.00. Following the completion of the sale, the chief executive officer now directly owns 439,307 shares in the company, valued at approximately $51,113,369.45. The trade was a 0.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Seamus Mulligan bought 100,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, May 9th. The shares were purchased at an average cost of $98.26 per share, with a total value of $9,826,000.00. Following the acquisition, the director now directly owns 100,000 shares of the company's stock, valued at approximately $9,826,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 3,000 shares of company stock worth $355,925. Company insiders own 4.30% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Morgan Stanley cut their price objective on Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. JPMorgan Chase & Co. raised their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Royal Bank Of Canada lowered their price target on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Wall Street Zen downgraded Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Finally, Barclays reissued an "overweight" rating and issued a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $184.00.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.